Healthcare News 16

• a natural response by competitor
• A new treatment for a major problem.
• A triple combination for H1N1: good in principle
• Abbot will benefit in long run with acquisition of Evalve.
• Afresa suppresses gluconeogenesis more readily than Humalog or Exubera
• Amylin Partners with Biocon to Develop Novel Diabetes Therapeutic
• Amyloid Beta does not correlate to Alzheimer Disease.
• Animal vaccine maker Merial expands Nanchang China plant
• Another tnf blocking agent?
• Antagonists: Are They Too Hot to Handle?
• Arena Announces BLOSSOM Phase 3 Data
• Article in NEJM argues for taxation of sugar-sweetened beverages
• ASTRO/ACRO help win the fight against Reimbursement Cuts for Radiation Oncology
• BD to Acquire Handy Lab
• Beckman Coulter Posts Strong 3Q Revenue Growth
• Boehringer Ingelheim Announces Conclusion of Phase 3 Clinical Trials
• CDC Outlines H1N1 Test Guidelines
• Cepheid Expects H1N1 FDA Approval
• Cepheid Reports Lower 3Q Revenues but Beat Estimates
• Cladribin: oral formulation for the treatment of multiple sklerosis.
• Clarification of Benefits , Allow Cost Comparisions and Speed Claims Payments
• Clik-STAR to give Sanofi-aventis more coverage
• Clinical efficacy for Linagliptin - results from phase III trials
• Clinical Labs Could Benefit from New Legislation
• Consolidation Continues in Life Sciences
• Contact Lens Nirvana: Hyperpermeable One Day
• Convenient for patients, and maybe for doctors
• Court Denies Lawsuit Dismissal Motion by Myriad Genetics and Others
• Critical thinking and creativity in AD research
• Death due to HPV vaccine....NOT
• Delcath Phase III trial for metastatic melanoma completes enrollment
• Dell Positions Itself for the Federal Health IT Spending Spree
• denosumab approval delayed
• Diabetes Care Article Shows Sustained Benefits of CGM
• Drug Advertising Paradox
• Electronic Health Record Data will be an Industry Gold Mine
• Epigenomics Reports Excellent 3Q Returns
• Expanding Treatment Options for Prostate Cancer
• Express Scripts feeling Growing Pains
• Fampridine Clears Major Hurdle at FDA Review Panel
• Fampridine's FDA Pre-Meeting Report Raises Concerns About Efficacy and Safety
• Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
• FDA Approval for Vermillion's Ovarian Cancer Test
• FDA Publishes H1N1 Diagnostic Test Guidance
• Five Steps to Healthcare Reform
• Five Steps to Healthcare Reform
• Flu Emergency Calls for all Alternatives to be Considered
• For Medicare, There's No Place Like Home
• Four of Five H1N1 Vaccines Approved
• Fresh Hope for Diabetes Patients
• From a physician point of view
• FTY720 for Relapsing forms of MS
• Genetic Patent Recommendations Could Impact Diagnostic Companies
• Genomic Health Posts a 41% Q3 Revenue Increase
• Gen-Probe Acquires Prodesse
• Gen-Probe Files Patent Lawsuit Against BD
• Gen-Probe Spins Off Roka Bioscience
• Ghana Targets Health Tourism Boom: More Evidence of Globalization
• Glenmark Stock worth considering!!!
• Government Run Health Insurance Fails
• GSK's cervical cancer vaccine Cervarix gains approval in Japan
• GSK's new venture into Duchenne's makes sense
• Health Care Reform Debate 2009 ~ Blind Rush to Rash Decisions
• Health Insurers may have Sealed their own Fate
• Health Tourism in Ghana a reality or a dream?
• Healthy if You're Wealthy: Ghana offers Choices
• Herceptin for Her2 + gastric cancer, If you can find one
• HIV/AIDS DRUG-INDUS BIOTECH
• HIV: One Step Closer, but...
• How much market will MADIT-CRT drive?
• Improvements to CV risk factors, but magnitude very low
• India is a good clinical trial destination with new CROs in future
• Intarcia Begins Enrolling Patients for Phase 2 Trials of ITCA 650
• Is a new delivery system for a old drug such a big deal?
• Is GE Global Research Developing a Portable Solar-Powered Ultrasound Device?
• Is the End of the Beginning of Diabetes Coming?
• It's Time for Health Care Reform--Not Just Health Insurance Reform!
• Lantus Wins, Mannkind Loses
• LEAD-6 Extension Trial Results Announced-- Look Positive for Novo Nordisk
• Liquid-Based Cytology Found Not Superior to Conventional PAP
• Lumigan X EU Committee Recomendation
• Major Turnaround- NEJM VADT Correction Shows MVC Benefits of Intensive Control
• Mastinib for treatment of Rheumatoid arthritis
• Merck and Qiagen Team Up to Fight HPV
• Metagliptin too?
• Metanalyses, Metapsychoses
• Mobile Advertising Set To Soar ? Yes, But What Is The Engine For Growth
• More MDs Should Provide Guidance
• Most Efficient Way of New Drug Discovery
• Myriad Genetic Receives Pancreatic Gene License
• New hopes for Influenza Prevention & treatment
• New Innovative Delivery System
• New Sample Prep Company
• New twist in ABCD algorithm
• Newer info on Enbrel, not really that surprising.
• NICE guidelines for usage of biologics and possible implications in the US
• NO BRAINER: Genentech Prefers to Promote Lucentis over Avastin for Wet ARMD
• Novartis, Sleeping Giant Wakes-Up in China
• Novo Nordisk's Liraglutide Wins in Obesity Too
• Omapro will fill a CML void
• Oral MS Medications
• Oral treatment modify the clinical course of multiple sclerosis: Teriflunomide
• Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance
• Panvax H1N1 approval good for Swine Flu Pandemic Control
• Parkinson's Drug
• Particle Beam Radiation Therapy (PBRT) life saving technology but who will pay?
• Particle Beam Technology - Costly and a limited utility
• Peplin merger with Leo pharma
• Percutaneous valve repair – next battle among cardiovascular device companies?
• Pfizer fine for inappropriate bextra marketing
• Pharm awakens to accountability
• Pharma Outsourcing: Where Will it End?
• Plexxikon Drug for Melanoma Continues to Show Great Promise
• Potential impact of large clinical trial on Liquid based cytology market
• Presta Trial shows good results for Enbrel
• Qiagen's Acquisition Expands High Value Diagnostics Position
• Quest Diagnostics Receives Second FDA H1N1 EUA
• Quest Diagnostics to Offer New Colorectal Cancer Test
• Quidel Partners with BioHelix
• Ranbaxy in EU Anti Trust Net
• REGORAFENIB joins a crowd of TKI's for RCC
• Researchers herald 'breakthrough' skin cancer therapy
• Rituxan tests positive in Phase III trial
• Roche Receives H1N1 FDA Emergency Use Authorization
• Roche's Herceptin provides impressive survival benefit
• SACGHS Genetic Testing Report Slammed
• Sandoz’ Generic Drug Push in Japan: Good Timing; Interesting Challenges
• Sanofi Pasteur Commends Results of First HIV Vaccine
• Saxagliptin - third gliptin on the EU market
• Senate Finance Bill has the Greatest Potential to Reform Health Care Delivery
• Sequenom Sued by Shareholders
• Shares That Go Bump In The Night
• Should we use 3D imaging for “routine orthodontic cases”?
• Small molecule inhibitors in RA.
• Social Networking & Search Engine Optimization
• Solar-Powered Portable Medical Imaging Devices Are Coming Soon
• Starpharma gets US patent for use of VivaGel for protection against STIs
• Stelara new Option for Psoriasis
• Succesful new treatment for Lupus
• Swine Flu Could Benefit Reference Labs
• Synta Drug for Metastatic Melanoma Not Dead Yet (?)
• Talecris Biotherapeutics Proposes IPO; Hits Favorable Timing Window
• Tardy with their own combo!!
• Tecnis Multifocal Outperforms Competitors
• The Future of Dentistry in 3-D: Digitally Mapping the Human Skull
• The good news is that these drugs are already approved
• The Holy Grail of Saving Lives and Saving Money Found to be Achievable--Again!
• The Logical Next Step for Abbott
• Thermo Fisher Could Benefit From Consolidation
• Third to market but any advantages?
• Triple negative Breast Cancer Strategies
• TRPs as Analgesic Drug Targets: Using HC-030031 to Probe the Role of TRPA1
• TRPV1 Agonists: 500 Years in Development
• Turn around signs seen in healthcare !!! Dr. Reddy's & Ranbaxy beat the trend!!!
• Update on tocilizumab treatment for RA
• Updates on Januvia
• Watershed Intraocular Lens: The Light Adjsutable Lens (Calhoun Vision)
• We need to learn more about ProSavin Phase I/II Trial in Parkinson’s disease
• What does Solvay offer to a bidder ?
• What is potential future for Sequenom in prenatal testing.
• What Will Help The Poor?
• What's Next for Sequenom?
• Which Combination of Drugs for Influenza?
• Why a third ME TOO drug?
• Will Bundles of Healthcare Payments Bring Joy to Anybody?
• Will Quest Acquire Vermillion?
• Will the alternative become a leader?
• Will Varian's EMR restrain company growth?
• Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?